Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients

What Was Tested

This randomized controlled trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.

Chronic kidney disease (CKD) drives onerous human and healthcare costs, underscoring an urgent need to avert disease progression.

Who Took Part

According to the abstract, 126 adults were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Changes in estimated glomerular filtration rate (eGFR) were analyzed post hoc in 126 adults with SHPT, stage 3-4 CKD, and low serum 25-hydroxyvitamin D (25D) treated for 1 year with ERC in pivotal trials.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 1 year.

Calcium, phosphorus, 25D, 1,25-dihydroxyvitamin D (1,25D), iPTH, eGFR, fibroblast growth factor-23 (FGF23), bone turnover markers (BTMs), and urine albumin-to-creatinine ratio (uACR) were measured at baseline and regular intervals.

What Was Measured

The subject headings attached to it are Hyperparathyroidism, Secondary, Parathyroid Hormone, Glomerular Filtration Rate, Disease Progression, Fibroblast Growth Factor-23, Renal Insufficiency, Chronic and Vitamin D.

Author keywords: Chronic kidney disease, Extended-release calcifediol and Secondary hyperparathyroidism.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in 126 adults in people with hyperparathyroidism over 1 year.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (American journal of nephrology), a journal based in Switzerland.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.